| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003010196A3 Variants and exons of the glyt1 transporter |
| 04/29/2004 | WO2003003006A3 New potent, selective and non toxic c-kit inhibitors |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002078626A3 Therapeutic combinations for cardiovascular and inflammatory indications |
| 04/29/2004 | WO2002072630A3 Nucleic acid-associated proteins |
| 04/29/2004 | WO2002070669A3 Secreted proteins |
| 04/29/2004 | WO1999028440A9 Nucleic acid encoding mammalian ubr1 |
| 04/29/2004 | US20040082934 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 04/29/2004 | US20040082764 Complex of antibodic and antibiotic with carrier |
| 04/29/2004 | US20040082664 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition |
| 04/29/2004 | US20040082659 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 04/29/2004 | US20040082643 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus |
| 04/29/2004 | US20040082641 Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| 04/29/2004 | US20040082640 Use of cox-2 inhibitors for preventing immunodeficiency |
| 04/29/2004 | US20040082638 Compounds, compositions and methods |
| 04/29/2004 | US20040082635 Fused cyclic compounds and medicinal use thereof |
| 04/29/2004 | US20040082614 Chlamydia infections; anticholesterol agents; cardiovascular disorders; using mixture containing azithromycin |
| 04/29/2004 | US20040082613 Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| 04/29/2004 | US20040082605 Use |
| 04/29/2004 | US20040082597 Use of CRF antagonists and related compositions |
| 04/29/2004 | US20040082596 Novel carbamate-substituted pyrazolopyridine derivatives |
| 04/29/2004 | US20040082594 Novel uses of combined 5-ht 1a agonists and serotonin reuptake inhibitors |
| 04/29/2004 | US20040082590 Dietetics; antidiabetic agents; sexual disorders |
| 04/29/2004 | US20040082583 Chemical compounds |
| 04/29/2004 | US20040082567 Antiproliferative agents; anticancer agents; fungicides; antiinflammatory agents |
| 04/29/2004 | US20040082562 Novel inhibitors of IMPDH enzyme |
| 04/29/2004 | US20040082559 Vitronectin receptor antagonists |
| 04/29/2004 | US20040082557 Methods for treating estrogen-dependent disorders |
| 04/29/2004 | US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
| 04/29/2004 | US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
| 04/29/2004 | US20040082552 Synergistic mixture; induction mutation; viricides; therapy for drug resistancee |
| 04/29/2004 | US20040082543 Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| 04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
| 04/29/2004 | US20040082537 Powder comprising water-containing beta-maltose crystals and production process and use thereof |
| 04/29/2004 | US20040082517 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/29/2004 | US20040082507 Use of GLP-1 and GLP-2 peptides |
| 04/29/2004 | US20040082504 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 04/29/2004 | US20040082064 Stimulanting immunology response; calibrating success of organ, tissue transplant; polymerase chain reaction analysis; administering immunosuppressants |
| 04/29/2004 | US20040081998 Novel carboxylesterase nucleic acid molecules, proteins and uses thereof |
| 04/29/2004 | US20040081976 Genomic screen for epigenetically silenced tumor suppressor genes |
| 04/29/2004 | US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents |
| 04/29/2004 | US20040081712 Soy protein, phytoestrogens and dietary fibres and compositions |
| 04/29/2004 | US20040081699 Quickly disintegrate in aqueous media |
| 04/29/2004 | US20040081697 Single daily dose of insulin sensitizer and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081677 Gel formulations of hydroxypyridone derivatives, which contain solvents and hydrophilic gel-forming agents make possible a high release of the active compound |
| 04/29/2004 | US20040081664 Oral delivery of a botanical |
| 04/29/2004 | US20040081650 Inflammatory mediator antagonists |
| 04/29/2004 | US20040081642 Methods of treating vascular diseases characterized by nitric oxide insufficiency related applications |
| 04/29/2004 | US20040081626 Liquid mixture containing active materials; suspension drops in carrier gas; drug delivery; asthma therapy |
| 04/29/2004 | DE10246340A1 Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung Combination preparation of hyaluronic acid and at least one local anesthetic and its use |
| 04/29/2004 | CA2542620A1 Method of treating snoring and other obstructive breathing disorders |
| 04/29/2004 | CA2503075A1 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | CA2502032A1 Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
| 04/29/2004 | CA2502027A1 A method of treating vasomotor symptoms comprising a compound having norepinephrine reuptake inhibitor activity and 5-ht2a antagonistic activity |
| 04/29/2004 | CA2501959A1 Therapeutic treatment |
| 04/29/2004 | CA2501556A1 Remedy for hormone-dependent cancer |
| 04/29/2004 | CA2501298A1 Method of modifying the release profile of sustained release compositions |
| 04/29/2004 | CA2501201A1 Gastric acid secretion inhibiting composition |
| 04/29/2004 | CA2501093A1 Combinations of benzodithiazoles and cox-2 inhibitors for the treatment of pain |
| 04/29/2004 | CA2497780A1 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 04/28/2004 | EP1413332A1 Use of 2,5-dihydroxybenzenesulphonic acid derivatives in the production of a medicament used to potentiate the effect of other drugs in the treatment of erectile dysfunction |
| 04/28/2004 | EP1413331A2 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) for vascular indications |
| 04/28/2004 | EP1413315A1 Sustained-release medicines |
| 04/28/2004 | EP1413314A1 Medicinal compositions |
| 04/28/2004 | EP1413304A1 Use of combination of carnitine and lipoic acid for restoring mitochondrial function |
| 04/28/2004 | EP1413303A1 Swine growth promoters and method of promoting swine growth |
| 04/28/2004 | EP1413299A2 Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function |
| 04/28/2004 | EP1413295A1 Sustained release composition for oral administration of drugs |
| 04/28/2004 | EP1413201A2 Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals |
| 04/28/2004 | EP1413174A1 Mounting arrangement for auxiliary burner or lance |
| 04/28/2004 | EP1412754A1 Diagnostic methods and agents |
| 04/28/2004 | EP1412529A2 Methods for assessing the risk of obesity based on allelic variations in the 5'-flanking region of the insulin gene |
| 04/28/2004 | EP1412523A2 Methods of profiling gene expression, protein or metabolite levels |
| 04/28/2004 | EP1412499A2 Cytokine polypeptides |
| 04/28/2004 | EP1412498A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 04/28/2004 | EP1412484A1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
| 04/28/2004 | EP1412477A2 GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE |
| 04/28/2004 | EP1412389A1 Binding agents with differential activity |
| 04/28/2004 | EP1412388A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 04/28/2004 | EP1412387A2 Transporters and ion channels |
| 04/28/2004 | EP1412386A2 USE OF PEPTIDE FRAGMENTS OF THE CALCIUM CHANNEL $g(A)-1 SUBUNIT, OPTIONALLY COMPRISING MUTATIONS, FOR SCREENING MOLECULES OF THERAPEUTIC INTEREST |
| 04/28/2004 | EP1412374A2 Novel pgc-1 isoforms and uses therefor |
| 04/28/2004 | EP1412360A1 COMBINATION THERAPY OF AN SODm AND A CORTICOSTEROID FOR PREVENTION AND/OR TREATMENT OF INFLAMMATORY DISEASE |
| 04/28/2004 | EP1412357A1 Beta-amino tetrahydroimidazo(1,2-a)pyrazines and tetrahydrotriazolo(4,3-a)pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 04/28/2004 | EP1412354A1 DERIVATIVES OF TRIAZOLYL-IMIDAZOPYRIDINE AND OF THE TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE ADENOSINE A 2a? RECEPTOR AND THEIR USE AS MEDICAMENTS |
| 04/28/2004 | EP1412317A1 Retinoid derivatives with antiangiogenic, antitumor and proapoptotic activities |
| 04/28/2004 | EP1412029A2 Combinations comprising epothilones and pharmaceutical uses thereof |
| 04/28/2004 | EP1411998A1 Stents with vitronectin receptor antagonists against restenosis |
| 04/28/2004 | EP1411985A1 Treatment of parasitic disease |
| 04/28/2004 | EP1411984A2 Combination medicament for treatment of neoplastic diseases which contains cyanoguanidine ikk inhibitors and a second anti-neoplastic drug |
| 04/28/2004 | EP1411982A1 Modulators of p-selectin glycoprotein ligand 1 |
| 04/28/2004 | EP1411980A2 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |